Type 2 Diabetes, Evidence-Based Medicine & The Reign of Confusion

Evidence-based medicine (EBM) is getting a lot of attention these days. Like most topics, it has its ardent fans and die-hard opponents. To some, EBM is cookbook medicine, with too many rules and too little room for individual clinical judgment. On the other side of the controversy are EBM proponents who feel that arming physicians with guidelines, best practices and protocols brings a much needed dose of standardization into the Wild West world of healthcare decision making. Read more → →

All that Glitas is Not Gold – Musings on Pharma Marketing & Type 2 Diabetes

In the past several years, the second-generation glitazones Avandia (rosiglitazone) and Actos (pioglitazone) – once touted as breakthroughs that could reduce cardiovascular mortality in patients with type 2 diabetes – have been tarnished by controversy. The story of the glitazones (also known as thiazolidinediones or TZDs) reflects everything that is good, bad and ugly about the pharmaceutical industry. Read more → →